Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT antibody persistence follow-up in adolescents
2012-005641-21Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Vaccines & Immunotherapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine, meningococcal ACYW135 vaccine in meningococcal disease, sponsored by GSK.
02
Drugs
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccinemeningococcal ACYW135 vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-005641-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005641-21.